PATENT CLAIM ANALYSIS

Application Number: 16114002
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-06
Patent Classification: ["514", "001300"]

Abstract:
Depression and PTSD are treated by administration of hCG, or an hCG analog, or a prodrug or metabolite of hCG or an hCG analog, in an amount equivalent to a subcutaneous dose of 50-200 IU, preferably 120-170 IU, more preferably 140-160 IU, of hCG per day.

Claim (Index 21):
The method of  claim 19 , wherein the anxiety disorder is a disorder that includes a symptom of re-experiencing one or more events related to the serious injury.

Metadata:
- Claim Count in Document: 59.0
- Percentile: 96.0
- Lexical Diversity: 1.70968
- Patent Class: 514.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15268979', '13211101', '13633739', '10817312', '11979265']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7712825679831573
- 35 USC 102 Novelty (BERT): 0.5518301902411868
- Combined Prediction Score: 0.7493373302089603
- Mean Citation Score: 305.1488700000001
- Max Citation Score: 448.59277
- Similarity Product: 225.44495166494133

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test